These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 3495487)
1. Binding and cytotoxic effect of ricin toxin on multivalent hybrid antibody-coated target cells. Laky M; Mota G; Moraru I; Ghetie V Immunol Lett; 1987 Jan; 14(2):127-32. PubMed ID: 3495487 [TBL] [Abstract][Full Text] [Related]
2. In vivo follow up of the cytotoxic effect of ricin toxin vectorized by multivalent hybrid antibody on target cells. Moa G; Nicolae M; Laky M; Bancu A; Moraru I Immunol Lett; 1988 Feb; 17(2):177-82. PubMed ID: 3258846 [TBL] [Abstract][Full Text] [Related]
3. Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. Thorpe PE; Ross WC; Brown AN; Myers CD; Cumber AJ; Foxwell BM; Forrester JT Eur J Biochem; 1984 Apr; 140(1):63-71. PubMed ID: 6608447 [TBL] [Abstract][Full Text] [Related]
4. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Zovickian J; Johnson VG; Youle RJ J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171 [TBL] [Abstract][Full Text] [Related]
5. Protein A vectorized toxins--I. Preparation and properties of protein A-ricin toxin conjugates. Ghetie MA; Laky M; Moraru I; Ghetie V Mol Immunol; 1986 Dec; 23(12):1373-9. PubMed ID: 3493427 [TBL] [Abstract][Full Text] [Related]
6. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity. Pietersz GA; Kanellos J; McKenzie IF Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Raso V; Ritz J; Basala M; Schlossman SF Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA). Pelham JM; Meyer BF; Herrmann RP; Davis RE; Raphael CL; Kraft N; Atkins RC Pathology; 1987 Apr; 19(2):124-30. PubMed ID: 2969499 [TBL] [Abstract][Full Text] [Related]
9. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain. Ramakrishnan S; Houston LL Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765 [TBL] [Abstract][Full Text] [Related]
10. Experimental model for testing the efficiency of immunotoxins administered in vivo: evaluation of two ricin A-chain--multivalent antibody immunotoxins. Moţa G; Mărgineanu M; Marcheş R; Nicolae M; Bancu A; Moraru I Immunol Lett; 1989 Mar; 20(4):283-91. PubMed ID: 2785502 [TBL] [Abstract][Full Text] [Related]
11. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6. Hara H; Luo Y; Haruta Y; Seon BK Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562 [TBL] [Abstract][Full Text] [Related]
13. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies]. Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780 [TBL] [Abstract][Full Text] [Related]
14. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. Colombatti M; Johnson VG; Skopicki HA; Fendley B; Lewis MS; Youle RJ J Immunol; 1987 May; 138(10):3339-44. PubMed ID: 2437188 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328 [TBL] [Abstract][Full Text] [Related]
17. In vivo follow-up of the cytotoxic effect of protein A--ricin toxin conjugate, on antibody-coated target cells. Moţa G; Mărgineanu M; Nicolae M; Bancu A; Moraru I Immunol Lett; 1988 May; 18(1):67-72. PubMed ID: 3378832 [TBL] [Abstract][Full Text] [Related]
18. Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain. Embleton MJ; Charleston A; Robins RA; Pimm MV; Baldwin RW Br J Cancer; 1991 May; 63(5):670-4. PubMed ID: 2039690 [TBL] [Abstract][Full Text] [Related]
19. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. Webb KS; Poulton SH; Liberman SN; Walther PJ J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412 [TBL] [Abstract][Full Text] [Related]
20. A monoclonal immunotoxin against laryngeal carcinoma cells. Zenner HP Otolaryngol Pol; 1990; 44(3):214-5. PubMed ID: 2255554 [No Abstract] [Full Text] [Related] [Next] [New Search]